News | March 16, 2026
First patient dosed in trial of novel drug targeting limb-threatening artery disease
The trial will enroll up to 42 patients in Finland across four cohorts
The trial will enroll up to 42 patients in Finland across four cohorts
The conflict is also triggering a widening public health emergency
Nearly 12 million people are estimated to be living with glaucoma, making the country one of the worst affected globally
The alliance directly links VivaMed’s computational drug hypotheses with Syngene’s preclinical development capabilities
The data highlights its RSV vaccine cuts hospitalizations in older adults
The approval follows the pivotal Phase III ARANOTE trial, which demonstrated that darolutamide plus ADT cut the risk of radiological progression or death by 46% compared to placebo plus ADT
Glucon-D maintained its leadership position with a 59% MAT market share
The Union Budget makes a clear and timely choice by placing biopharma at the centre of India’s next manufacturing wave
This deal marks a major step for Alteogen as it pushes its Hybrozyme platform deeper into the oncology market
India in the Changing Landscape of Life-Sciences Research & Development
Subscribe To Our Newsletter & Stay Updated
